Document is current
Any future updates will be listed below
-
Authors
Didriksson, Ingrid https://orcid.org/0000-0003-1334-7583
Lengquist, Maria
Spångfors, Martin
Leffler, Märta
Sievert, Theodor
Lilja, Gisela
Frigyesi, Attila
Friberg, Hans
Schiopu, Alexandru
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04974775 at ClinicalTrials.govDocuments that mention this clinical trial
Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients
https://doi.org/10.1186/s40560-024-00740-4
-
Funding
Funding for this research was provided by:
Ministerul Educaţiei Naţionale (PNRR-C9/18-CF148)
Socialstyrelsen (2019:YF0053)
Riksförbundet HjärtLung (21004021, 21023322)
Lund University
- License Information
-
More Information
Article History
Received: 21 May 2024
Accepted: 27 June 2024
First Online: 9 July 2024
Declarations
:
: Ethical approval was acquired from the Swedish Ethical Review Authority (2020/01955, 2020/03483 and 2020/05233). Written informed consent was obtained on ICU admission, before ICU discharge or at the 3-month follow-up as suitable for surviving participants; for deceased patients, consent was presumed according to the approval from the Ethical Review Authority. The study was registered on ClinicalTrials.gov Identifier: NCT04974775 on April 28, 2020.
: Not applicable.
: The authors declare that they have no competing interests.
